We’re making another trim in a stock that’s about $10 per share higher than our sale last week.
Source
We’re taking some profits in a health winner but still see stock as right for this market
Health
CDC takes down more than a dozen webpages on sexual and gender identity, health equity
A sign for the CDC sits outside of their facility at the Centers for Disease Control and Prevention Roybal campus in Atlanta, Georgia, U.S., May 30, 2025. Megan Varner | Reuters More than a dozen pages on the Centers for Disease Control and Prevention website related to sexual and gender identity, health equity, and other […]
Read More
Health
We’re buying the dip in a health and life sciences stock that has gone down enough
We’re buying 20 more shares of Danaher at roughly $180 each. Following Thursday’s trade, Jim Cramer’s Charitable Trust will own 470 shares of DHR, increasing its weighting to about 2.31% from about 2.22%. While Danaher has certainly been one of a handful of problematic stocks in the portfolio, we are stepping into the name here, […]
Read More
Health
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to […]
Read More